Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CervoMed (CRVO) EBITDA Margin (2023 - 2025)

CervoMed's EBITDA Margin history spans 8 years, with the latest figure at 2393.3% for Q3 2025.

  • For Q3 2025, EBITDA Margin fell 215560.0% year-over-year to 2393.3%; the TTM value through Sep 2025 reached 417.26%, down 29980.0%, while the annual FY2024 figure was 166.71%, 13632.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 2393.3% at CervoMed, down from 357.3% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 140.87% in Q3 2023 and bottomed at 2393.3% in Q3 2025.
  • The 3-year median for EBITDA Margin is 237.69% (2024), against an average of 372.89%.
  • The largest annual shift saw EBITDA Margin soared 18127bps in 2024 before it plummeted -215560bps in 2025.
  • A 3-year view of EBITDA Margin shows it stood at 94.85% in 2023, then crashed by -230bps to 313.27% in 2024, then plummeted by -664bps to 2393.3% in 2025.
  • Per Business Quant, the three most recent readings for CRVO's EBITDA Margin are 2393.3% (Q3 2025), 357.3% (Q2 2025), and 257.06% (Q1 2025).